Three drugmakers — Eli Lilly, Novo Nordisk and Sanofi — will testify at the House Energy and Commerce committee hearing on insulin prices April 10, according to The Hill.
Pharmacy
Cigna and Express Scripts launched a program that limits members' out-of-pocket insulin costs to $25 for a 30-day supply, the companies said April 3.
Avella Specialty Pharmacy, a subsidiary of UnitedHealth Group's pharmacy benefit manager OptumRx, is ending its drug compounding services at two Houston sites, according to the Houston Chronicle.
After missing analysts' second-quarter sales and earning expectations, Walgreens Boots Alliance vowed to cut more than $1.5 billion in costs by fiscal year 2022, according to CNBC.
A federal judge in New York has ruled that Novartis must face trial in a case accusing the drugmaker of paying millions of dollars in kickbacks to physicians to boost prescription rates, according to Reuters.
Advertisement
An Oklahoma pharmacy owner has been charged with orchestrating a scheme that defrauded Medicare and Medicaid out of more than $1 million.
Martin Shkreli was placed in solitary confinement after a report surfaced that the infamous "pharma bro" was using a contraband cellphone to run his pharmaceutical company from prison, according to Forbes.
The U.S. Health Resources & Services Administration launched a long-awaited website for safety-net providers participating in the 340B Drug Pricing Program April 1.
Novartis has agreed to acquire a subsidiary of IFM Therapeutics for a potential total of nearly $1.6 billion, including $310 million up front, and up to $1.27 billion in milestone payments, according to Reuters.
After facing pressure from federal regulators, Walgreens Boots Alliance is piloting several tobacco-free stores in the U.S., but doesn't plan to halt sales entirely, according to The Wall Street Journal.